6th April 2017
- 0 comments
6 April
A novel antibiotic, which has been developed in Scotland for the treatment of Clostridium difficile, will take a step closer to being brought to market following the completion of a further round of funding led by prominent angel investment syndicate, Archangels, for MGB Biopharma.
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage